title: Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease.
abstract: This study defined the clinical features and assessed the prognosis of 47 patients (17 males, 30 females, median age 63 years) with primary nodal marginal zone B-cell lymphoma. Forty-five per cent had stage IV disease. Hepatitis C virus serology was positive in 24%. According to the Follicular Lymphoma International Prognostic Index (FLIPI), 33% were classified as low-risk, 34% as intermediate-risk, and 33% as high-risk. The 5-year overall survival (OS) was 69%. In univariate analysis worse OS was associated with: FLIPI (P = 0.02), age > 60 years (P = 0.05) and raised lactate dehydrogenase (P = 0.05). In multivariate analysis, only FLIPI predicted a worse OS (P = 0.02).
authors.affiliation: Division of Haematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy. luca.arcaini@unipv.it
authors.forename: Luca
authors.initials: L
authors.lastname: Arcaini
authors.forename: Marco
authors.initials: M
authors.lastname: Paulli
authors.forename: Sara
authors.initials: S
authors.lastname: Burcheri
authors.forename: Andrea
authors.initials: A
authors.lastname: Rossi
authors.forename: Michele
authors.initials: M
authors.lastname: Spina
authors.forename: Francesco
authors.initials: F
authors.lastname: Passamonti
authors.forename: Marco
authors.initials: M
authors.lastname: Lucioni
authors.forename: Teresio
authors.initials: T
authors.lastname: Motta
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Canzonieri
authors.forename: Mauro
authors.initials: M
authors.lastname: Montanari
authors.forename: Emanuela
authors.initials: E
authors.lastname: Bonoldi
authors.forename: Andrea
authors.initials: A
authors.lastname: Gallamini
authors.forename: Lilj
authors.initials: L
authors.lastname: Uziel
authors.forename: Monica
authors.initials: M
authors.lastname: Crugnola
authors.forename: Antonio
authors.initials: A
authors.lastname: Ramponi
authors.forename: Francesca
authors.initials: F
authors.lastname: Montanari
authors.forename: Cristiana
authors.initials: C
authors.lastname: Pascutto
authors.forename: Enrica
authors.initials: E
authors.lastname: Morra
authors.forename: Mario
authors.initials: M
authors.lastname: Lazzarino
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D016174:Hepacivirus; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D016130:Immunophenotyping; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000473:pathology* / Q000821:virology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D035583:Rare Diseases / Q000188:drug therapy / Q000473:pathology* / Q000821:virology; D016019:Survival Analysis; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone